Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus MPI STANNOUS DIPHOSPHONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus MPI STANNOUS DIPHOSPHONATE.
MPI INDIUM DTPA IN 111 vs MPI STANNOUS DIPHOSPHONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Stannous diphosphonate is a radiopharmaceutical agent that forms a complex with technetium-99m; it localizes to areas of increased bone turnover by chemisorption to hydroxyapatite crystals, thereby enabling bone scintigraphy.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
Adult: 1-4 mg administered intravenously, single dose for bone scintigraphy.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Terminal elimination half-life: Approximately 2.5 hours for the diphosphonate component; the stannous ion is cleared more slowly. Clinically, this allows rapid bone uptake and background clearance for imaging within 2–4 hours post-injection.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Renal: >90% of the administered dose is excreted unchanged in the urine within 24 hours. Biliary/fecal: Minimal (<2%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical